This regulatory framework restricts the prescribing freedom of physicians, as the 2023 European Society of Cardiology (ESC) guideline, along with its 2024 corrigendum, clearly recommends the use of SGLT2 inhibitors and GLP-1 RAs in patients with established cardiovascular disease or at high cardiovascular risk, regardless of HbA1c levels (Class I, Level A evidence) [87]. This evidence concerns the gene GLP1R and cardiovascular disorder.